These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29070472)

  • 1. [Breakthrough bleeding in adult patients with severe hemophilia A receiving low- and intermediate-dose FVIII for tertiary prophylaxis: characteristics and influencing factors].
    Qiu SQ; Zhuang JM; Zhou X; Yin RX; Liu ZQ; Ma F; Li YJ; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 Oct; 37(10):1391-1395. PubMed ID: 29070472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].
    Zhuang JM; Sun XY; Zhou X; Liu ZQ; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Apr; 38(4):496-501. PubMed ID: 29735454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of FVIII doses on joint structure and function in adolescents with severe hemophilia A: mid-term results of a prospective cohort study].
    Meng L; Zhuang J; Sun X; Liu Z; Zhou X; Liu H; Zhou F; Li Y; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Apr; 41(4):536-542. PubMed ID: 33963712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study.
    Yao W; Xiao J; Cheng X; Feng G; Li C; Zhang X; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Zhao Y; Wu R
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):851-858. PubMed ID: 27920236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Individualized Preventive Treatment of Patients with Severe Hemophilia A Guided by Multiple Clinical Parameters and Pharmacokinetics.
    Wang Y; Yang Q; Zheng L; Wang X; Jiang W; Lu L; Yan L; Zhang M; Chen L
    Acta Haematol; 2022; 145(4):354-361. PubMed ID: 34879368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of short-term full-dose prophylaxis in adult Chinese patients with severe hemophilia A].
    Sun X; Zhuang J; Zhou X; Li H; Liu Z; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Sep; 38(10):1222-1227. PubMed ID: 30377129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of the effects of low/intermediate dose of coagulation factor Ⅷ on 30 adult patients with severe hemophilia A in a single center].
    Yuan YH; Xu PP; Xu YY; Liu S; Shao XY; Zhang WJ; Gong L; Zhou M; Chen B; Zhou RF
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):38-42. PubMed ID: 36987721
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
    Oldenburg J; Chambost H; Liu H; Hawes C; You X; Yang X; Newman V; Robinson TM; Hatswell AJ; Hinds D; Santos S; Ozelo M
    Adv Ther; 2024 Jun; 41(6):2267-2281. PubMed ID: 38616241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children.
    Chozie NA; Primacakti F; Gatot D; Setiabudhy RD; Tulaar ABM; Prasetyo M
    Haemophilia; 2019 Jul; 25(4):633-639. PubMed ID: 31044491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice Weekly Vs. Thrice Weekly Low-Dose Prophylactic Factor VIII Therapy in Children with Hemophilia A: An Open Label Randomized Trial.
    Gomber S; Singhal G; Dewan P; Upreti L; Sikka M
    J Trop Pediatr; 2022 Apr; 68(3):. PubMed ID: 35595254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A.
    Fernández-Bello I; Rode F; Álvarez-Román MT; Butta NV; Rivas-Muñoz S; Hernández-Moreno AL; de la Corte-Rodríguez H; Martín-Salces M; Larsen LF; Jiménez-Yuste V
    Eur J Pharm Sci; 2019 Feb; 128():215-221. PubMed ID: 30529268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A.
    Agosti P; Siboni SM; Scardo S; Torri A; Gualtierotti R; Peyvandi F
    Blood Adv; 2023 Dec; 7(23):7209-7215. PubMed ID: 37871302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
    Chowdary P; Fischer K; Collins PW; Cotterill A; Konkle BA; Blanchette V; Pipe SW; Berntorp E; Wolfsegger M; Engl W; Spotts G
    Thromb Haemost; 2020 May; 120(5):728-736. PubMed ID: 32369844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients.
    Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Ferrada A; Monte-Boquet E; Pérez-Alenda S; Bosch P; Querol-Giner F; Poveda JL
    Thromb Res; 2021 Sep; 205():99-105. PubMed ID: 34293540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.
    Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
    Curr Med Res Opin; 2017 Jul; 33(7):1223-1230. PubMed ID: 28326849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.
    Gruppo RA; Brown D; Wilkes MM; Navickis RJ
    Haemophilia; 2003 May; 9(3):251-60. PubMed ID: 12694514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.
    Fischer K; Collins P; Björkman S; Blanchette V; Oh M; Fritsch S; Schroth P; Spotts G; Ewenstein B
    Haemophilia; 2011 May; 17(3):433-8. PubMed ID: 21299740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
    Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study.
    Feldman BM; Pai M; Rivard GE; Israels S; Poon MC; Demers C; Robinson S; Luke KH; Wu JK; Gill K; Lillicrap D; Babyn P; McLimont M; Blanchette VS;
    J Thromb Haemost; 2006 Jun; 4(6):1228-36. PubMed ID: 16706965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.